KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. (TYO:4596) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders
|
2016 (the “Annual Meeting”) of Kubota Pharmaceutical Holdings
Co., Ltd. (the “Company”) was held on May 25, 2017. At the Annual
Meeting, votes representing 303,575 units of shares of the
Companys common stock, or approximately 99.5% of the total shares
entitled to vote, were present and voted to (i) approve the
amendment to the Articles of Incorporation of the Company to
reflect the change in location of the Companys head office and
(ii) elect the five nominees to the Board of Directors. The
proposals related to each matter are described in detail in the
Companys definitive proxy statement on Schedule 14A filed with
the Securities and Exchange Commission on April 27, 2017. The
voting results for each proposal are as follows:
|
1.
|
To approve the amendment to the Articles of Incorporation
of the Company to reflect the change in location of the Companys head office: |
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
302,900
|
|
2.
|
To elect the five nominees to the Board of Directors, each
to serve a one-year term |
|
Nominee
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
Shintaro Asako
|
302,475
|
|||
|
Ryo Kubota, M.D., Ph.D.
|
302,540
|
|||
|
Shiro Mita
|
302,528
|
|||
|
Eisaku Nakamura
|
302,512
|
|||
|
Robert Takeuchi
|
302,500
|
|
Item 8.01
|
Other Events.
|
the Financial Services Agency of Japan reporting the results of
the Annual Meeting. An English translation of the extraordinary
report is filed as Exhibit 99.1 to this Current Report on Form
8-K.
|
Item 9.01
|
Financial Statements and Exhibits.
|
||
|
(d) Exhibits.
|
|||
|
Exhibit Number
|
Description
|
||
|
99.1
|
Extraordinary report dated May 26, 2017.
|
||
About KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. (TYO:4596)
Kubota Pharmaceutical Holdings Co., Ltd. is a Japan-based company mainly engaged in the operation and management of subsidiaries. Its subsidiaries are mainly engaged in discovering and developing drug candidates to treat and slow the progression of sight-threatening ophthalmic diseases. The Company operates pharmaceutical development segment. It focuses on the development of oral formulation for age-related macular degeneration (AMD), glaucoma and dry eye syndrome. KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. (TYO:4596) Recent Trading Information
KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. (TYO:4596) closed its last trading session up +7.00 at 744.00 with 68,100 shares trading hands.
